GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gabather AB (OSTO:GABA) » Definitions » ROE % Adjusted to Book Value

Gabather AB (OSTO:GABA) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Gabather AB ROE % Adjusted to Book Value?

Gabather AB's ROE % for the quarter that ended in Dec. 2024 was 0.00%. Gabather AB's PB Ratio for the quarter that ended in Dec. 2024 was N/A. Gabather AB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.


Gabather AB ROE % Adjusted to Book Value Historical Data

The historical data trend for Gabather AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gabather AB ROE % Adjusted to Book Value Chart

Gabather AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.54 -15.81 -6.64 -10.64 -

Gabather AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81.26 - - - -

Competitive Comparison of Gabather AB's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Gabather AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gabather AB's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gabather AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Gabather AB's ROE % Adjusted to Book Value falls into.


;
;

Gabather AB ROE % Adjusted to Book Value Calculation

Gabather AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Gabather AB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gabather AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Gabather AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Gabather AB Business Description

Traded in Other Exchanges
N/A
Address
Forskargatan 20J, Byggn 215 N, Sodertalje, SWE, 151 36
Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.

Gabather AB Headlines

No Headlines